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Background: Castleman’s disease (CD) is a relatively rare disorder characterized by the benign proliferation of
lymphoid tissue. The combination of an occurrence of retroperitoneal pararenal CD with myasthenia gravis (MG)
is extremely rare.
Case presentation: The patient was admitted to our hospital for investigation of a retroperitoneal pararenal tumor
which had been coincidentally diagnosed at a local hospital where he was admitted because of MG. The patient
subsequently underwent an exploratory laparotomy and suffered from postoperative myasthenic crisis. Pathological
examination revealed a left retroperitoneal mass of CD (hyaline vascular type). There was no recurrence of disease
found after 7 months.
Conclusions: CD with MG is a rare condition. Postoperative myasthenic crisis is a severe complication. The
possibility of its occurrence must be in physicians’ minds and the risk of postoperative myasthenic crisis must
be carefully considered when evaluating MG patients undergoing surgery.
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Castleman’s disease (CD) was first described in 1956 by
Benjamin Castleman, who identified a series of patients
with solitary hyperplastic mediastinal lymph nodes contain-
ing small, hyalinized follicles and marked interfollicular
vascular proliferation [1]. The disease is predominantly
found in the mediastinum. Only 2% of CD cases have
been located in the pararenal and retroperitoneal area
[2]. The combination of an occurrence of retroperitoneal
pararenal CD with myasthenia gravis (MG) is extremely
rare. We report herein a rare case of CD in the pararenal
retroperitoneum associated with MG of a 29-year-old man,
who suffered from postoperative myasthenic crisis.
Case presentation
A 29-year-old man was admitted to our hospital on
February 19th, 2014, for investigation of a retroperiton-
eal pararenal tumor. The tumor had been coincidentally* Correspondence: csw123@sohu.com
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unless otherwise stated.diagnosed at a local hospital when he was admitted
because of MG with a clinical manifestation of increasing
upper and lower limb fatigue over 2 months. He was
treated with acetylcholinesterase inhibitors (pyridostigmine
at a dose of 3 × 30 mg) at the local hospital and clinical
remission was achieved. A mediastinal magnetic resonance
imaging (MRI) of local hospital did not show any evidence
for thymoma. On admission, physical examination did not
reveal any aberrations. Ultrasonography (US) demonstrated
a low echogenic mass measuring about of 5.4 × 5.2 cm in
size (Figure 1A). Unenhanced computed tomography (CT)
scan of abdomen presented a well-encapsulated mass of
homogeneous isodensity localized in the retroperitoneum
(Figure 1B). CTarteriograms showed that the mass received
its blood supply from abdominal aortic (Figure 1C). T1WI
of MRI showed a homogeneous low signal, while T2WI
and DWI demonstrated a slightly higher signal and the
center of the mass displayed patchy low signal (Figure 1D).
Electromyography exhibited that routine ulnar and median
motor and sensory nerve conduction studies were normal,
with no evidence for peripheral neuropathy; repetitivetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Unicentric hyaline-vascular Castleman’s disease in
a 29-year-old man. (A) Ultrasonography demonstrated a low
echogenic mass 5.4 × 5.2 cm in size (arrow) and there was no
significant relationship with the left kidney. (B) Unenhanced CT
of abdomen showed a well circumscribed, oval retroperitoneal
pararenal mass (arrow) with homogeneous density. (C) Arteriograms
showed arterial feeding to the mass from the abdominal aortic.
(D) T2WI showed a slightly higher signal and the center of the mass
displayed patchy low signal (arrow). (E) Photograph of a cut section
of resected specimen demonstrated alternating reddish-brown and gray
coloration. The reddish-brown areas represented cell components and
the gray areas (arrows) represented fibrous tissue corresponding to the
MRI findings. (F) Histological examination of the abdominal tumor
(×400). Hyaline degeneration of small vessels with a wide surrounding
by lymphoid follicle and lymphocytes arranged in an onion-skin pattern,
confirming a diagnosis of Castleman’s disease. Immunophenotyping
was positive for CD3, CD10, CD20, CD21, and CD23 antigens.
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of MG.
Preoperative biopsy for a definitive diagnosis was ex-
cluded in concern of the deep position and the possibility
of hemorrhea. Preoperative embolization cannot achieve
an efficient therapeutic result since the mass was not a
hemangioma nor were there any vascular malformations.
Although a definitive preoperative diagnosis was not
possible, surgical excision was performed on February
25th, 2014. A mid-abdominal laparotomy revealed an
oval mass with diffuse and rich vascularity located close
to the lateral side of the abdominal aortic, near the
anterior inferior part of the left renal. The surgical spe-
cimen was a well-circumscribed, encapsulated mass that
measured 5 × 4 cm with a cut reddish-brown surface
which changed to gray in the center (Figure 1E). An R0
resection was performed with a total blood loss of 200 mLwithout blood transfusion, and the operation time was
118 min. After 2 hours, the patient was sent back to
the ward. However, 30 min later, he suddenly developed
dyspnea with chest discomfort. Cyanosis appeared with
clammy extremities after 2 min. The oxygen saturation
dropped to 50 mmHg and cardiopulmonary resuscitation
was implemented. Oxygen saturation then raised to
100 mmHg immediately, which proved that the dyspnea
was caused by weakness of the respiratory muscles. The
patient was transferred to the intensive care unit (ICU)
after endotracheal intubation. A CT of the lung was per-
formed on February 27th showing no sign of pulmonary
embolism except for pleural effusion. He was back to the
ward on March 3rd and discharged after 2 days. Histological
examination of the abdominal tumor revealed angiofollicu-
lar lymph node hyperplasia of the hyaline-vascular type
(Figure 1F). The patient came back to our clinic after one
month and took a US which showed no recurrence of the
disease. He received another US which also showed no
abnormality 4 months after discharge. Further follow-up
was made after 7 months and he lived free of disease.
Discussion
The two clinical types (unicentric and multicentric) of
CD have been sub-classified according to its histological
forms: hyaline-vascular type, plasma cell type, and mixed
type. Unicentric CD corresponds to the hyaline-vascular
variant (>90%), and multicentric disease corresponds
to the plasma cell variant. The unicentric type usually
occurs in young people and is asymptomatic and asso-
ciated with a benign clinical course, for which surgical
excision is the most effective treatment. By contrast,
multicentric CD is a systemic disease with lesions at
two or more separate anatomic sites and is associated
symptoms and laboratory abnormalities, such as anemia,
fever, weight loss, night sweats, hypergammaglobulinemia,
hypoalbuminemia, and elevated erythrocyte sedimentation
rate, which need systemic therapy. CD cases associated
with MG were mostly of the unicentric hyaline-vascular
type, as was the case presented herein. A series of CD
cases with MG have been previously reported [3-6], three
of which were of the multicentric type. Ishikawa et al.
reported that seven out of eight CD cases associated with
MG were of the unicentric hyaline-vascular type, and the
remaining one was of the multicentric mixed type [7].
CD is a great mimic and known to be associated with
autoimmune diseases such as peripheral neuropathy, cyto-
penias, systemic lupus erythematosus, Sjogren’s syndrome,
and MG. The overproduction of cytokines and interleukin
is believed to play a central role in the development of CD
and it is also associated with many clinical conditions
related to immune disease [8]. The immune activity of CD
may be the promoter of the antibody-mediated process of
MG [4]. Klein et al. reported that the immune dysregulation
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connection of CD and MG [9]. In CD, the overproduction
of IL-6, a product of activated T-lymphocytes, results in
increased B-cell differentiation with the emergence of
plasma cell clones and subsequent formation of autoanti-
bodies that initiate immunopathological reactions [10,11].
Several studies have suggested that IL-6 is involved in
MG, which would coincide with its activity as a promoter
of B-cell differentiation and proliferation and an inducer
of B-cell maturation into antibody plasma cells [12].
Less than 10 previous cases of CD associated with MG
have been reported in the world literature with no evidence
of hyperplasia or malignancy of the thymus in any of the
cases. Only three of the cases have reported that the mass
located in the retroperitoneum [3,5,13] and myasthenic
crisis occurred in two [3,13] out of the three, which
means our case is the third one to date.
The main complication of MG is myasthenic crisis,
characterised by a fast, marked decrease of muscle
strength and compromise of bulbar muscles with dyspho-
nia, dysphagia, and aspiration. The death rate following
myasthenic crisis has drastically decreased after the 1950s
from 80% to less than 10%, thanks to the use of early
mechanical ventilation, admission to ICU, anticholines-
terase drugs, steroid therapy, immunosuppression, and
plasmapheresis [14-16]. Prompt treatment of myasthenic
crisis leads to clinical improvement and can be life-saving.
In this case, our rapid and effective rescue contributed to
the uneventful survival and recovery of the patient.
Conclusions
CD with MG is a rare condition. CD itself is a benign
disease histologically, but postoperative myasthenic crisis
is a severe complication. Therefore, the possibility of its
occurrence must be remembered. The risk of postopera-
tive myasthenic crisis must be carefully considered when
evaluating MG patients undergoing surgery. Monitoring
of post-operative vital signs can help in the early detection
of complications.
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